Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We investigated oncogene-specific differences in these markers and clinical outcome.

Related collections

Most cited references 41

Record: found
Abstract: found
Article: not found

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodriguez-Abreu, Andrew G Robinson … (2016)

Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1).

0 comments Cited 2577 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Hossein Borghaei, Luis Paz-Ares, Leora Horn … (2015)

Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.

0 comments Cited 2206 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Rina Hui, Takayasu Kurata, Silvia Novello … (2018)

First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.

0 comments Cited 2083 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (iso-abbrev): J Immunother Cancer

Title: Journal for immunotherapy of cancer

Publisher: BMJ

ISSN (Electronic): 2051-1426

ISSN (Print): 2051-1426

Publication date (Electronic): August 2021

Volume: 9

Issue: 8

Affiliations

[1 ] Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

[2 ] Foundation Medicine Inc, Cambridge, Massachusetts, USA.

[3 ] Genentech Inc, South San Francisco, California, USA.

[4 ] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

[5 ] Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

[6 ] Department of Radiology, Breast Imaging and Interventional Center, The George Washington University, Washington, DC, USA.

[7 ] Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

[8 ] Pfizer Inc, New York, New York, USA.

[9 ] Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA JHeymach@MDAnderson.org.